UPDATE : Friday, May 24, 2019
상단여백
HanAll's global partner starts P2 trial of Graves' ophthalmopathy treatment
Immunovant, HanAll Biopharma's global partner, has begun administering ...
by Lee Han-soo  |  2019-05-24 14:44
라인
OliX confident of its age-related macular degeneration treatment’s efficacy
OliX Pharmaceutical said it plans to submit an investigational new drug app...
by Lee Han-soo  |  2019-05-23 13:48
라인
Sillajen, CHA Hospital to co-develop immunotherapy
Sillajen said Wednesday it has entered an agreement with CHA Bundang Hospit...
by Lee Han-soo  |  2019-05-22 18:26
라인
SK Bioscience's shingles vaccine increases market share
Skyzoster, the first shingles vaccine domestically developed by SK Bioscien...
by Lee Han-soo  |  2019-05-22 17:04
라인
Handok, Sanofi to promote vaccines jointly
Handok said Wednesday that it has agreed with Sanofi Pasteur to co-promote ...
by Lee Han-soo  |  2019-05-22 15:48
라인
‘Dupixent is sole systemic, long-term treatment for atopic dermatitis’
Sanofi Genzyme is strengthening its position in the local atopic dermatitis...
by Lee Han-soo  |  2019-05-22 14:44
라인
Ministry grants additional indication to MSD’s immunotherapeutic drug
Keytruda, immunotherapy from MSD, has obtained additional approval from the...
by Lee Han-soo  |  2019-05-21 14:55
라인
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too?
Japan’s Health Ministry warned that Eli Lilly’s breast cancer therapy Verze...
by Kim Yun-mi  |  2019-05-21 14:19
라인
Roche’s breast cancer drug gains more insurance benefits
The Ministry of Health and Welfare has granted additional reimbursement to ...
by Lee Han-soo  |  2019-05-21 10:44
라인
Bridge Biotherapeutics releases first-in-human study for idiopathic pulmonary fibrosis treatment
Bridge Biotherapeutics announced that the company has presented interim dat...
by Lee Han-soo  |  2019-05-20 15:29
라인
Saxenda's sales surge 3,000 times yoy in Q1
Novo Nordisk’s Saxenda (ingredient: liraglutide), an obesity treatment, is ...
by Lee Han-soo  |  2019-05-17 14:37
라인
Daewoong launches Nabota in US amid controversy
Daewoong Pharmaceutical said it has officially launched Nabota, its botulin...
by Lee Han-soo  |  2019-05-16 16:33
라인
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride
The Korean Diabetes Association (KDA)’s revised guideline for diabetes trea...
by Kim Yun-mi  |  2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery
The Ministry of Food and Drug Safety has approved PD-1 inhibitor immunother...
by Kim Yun-mi  |  2019-05-15 14:14
라인
EU lists Korea on drug standard whitelist
Korea's medical export to the European Union is expected to see strong ...
by Lee Han-soo  |  2019-05-15 13:25
라인
J&J's nasal spray depression treatment still met with some skepticism
Johnson & Johnson's Spravato (ingredient: esketamine), a new nasal spra...
by Lee Han-soo  |  2019-05-14 15:26
라인
‘MSD Korea’s foreign exec got drunk, sexually harassed female worker’
A foreign executive at MSD Korea not only sexually harassed a female employ...
by Jeong Sae-im  |  2019-05-14 11:53
라인
Korean companies excel multinational pharma’s R&D in investment-sales ratio
Local pharmaceutical companies surpassed multinational giants in research a...
by Lee Han-soo  |  2019-05-13 17:27
라인
Chinese patients vaccinate MSD’s product in Korea. Why?
An increasing number of Chinese female patients are visiting Korean obstetr...
by Lee Han-soo  |  2019-05-13 14:57
라인
US trade agency orders Daewoong to submit Nabota’s strain
The prolonged dispute between Medytox and Daewoong over the origin of Nabot...
by Lee Han-soo  |  2019-05-13 14:37
-12345678910-
‘Shareholders can surely win lawsuit against Kolon’‘Shareholders can surely win lawsuit against Kolon’
여백
Most viewed
여백
Opinion
[Reporter’s Notebook] ‘Wanna know what’s going on with MSD Korea?’
[Reporter’s Notebook] ‘Wanna know what’s going on with MSD Korea?’
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too
[Reporter’s Notebook]MFDS incapable of reviewing new drugs?
[Reporter’s Notebook]MFDS incapable of reviewing new drugs?
여백
Back to Top